A single-institutional retrospective observational study on evaluation of HER2 expression by immunohistochemical staining in unresectable advanced gastric cancer
Not Applicable
- Conditions
- Gastric Cancer
- Registration Number
- JPRN-UMIN000047115
- Lead Sponsor
- Sapporo City General Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 177
Inclusion Criteria
Not provided
Exclusion Criteria
1. Cases in which HER2_IHC has not been performed. 2. Patients judged by the principal investigator to be inappropriate as research subjects.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HER2 positive rate: sample type (biopsy / surgical specimen) and test submission date (Weekday / Weekend)
- Secondary Outcome Measures
Name Time Method 1. HER2 positive rate among all study subjects 2. Comparison of HER2 positive rate by sample collection date (WD/WE) for different sample types (biopsy/surgical specimen) 3. Comparison of formalin fixation time by sample collection date (WD/WE) 4. Comparison of formalin fixation time by sample type (biopsy/surgical specimen) 5. Comparison of formalin fixation time in the sample type (biopsy/surgical specimen) according to the sample collection date (WD/WE) 6. Comparison of formalin fixation time and HER2 expression rate by sample type (biopsy/surgical specimen) 7. The difference in formalin fixation time (all population/sample type/sample collection date) 8. Comparison of treatment results by HER2 status (positive/negative) (overall survival from the start of chemotherapy, duration of response to trastuzumab combination therapy, and response rate)